• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

显性肝性脑病是肝硬化急性失代偿患者新发感染的独立危险因素。

Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation.

机构信息

Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, UK.

Faculty of Medicine, Alexandria University, Alexandria, Egypt.

出版信息

Aliment Pharmacol Ther. 2022 Mar;55(6):722-732. doi: 10.1111/apt.16790. Epub 2022 Feb 1.

DOI:10.1111/apt.16790
PMID:35106777
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9303427/
Abstract

BACKGROUND

The occurrence of overt hepatic encephalopathy (OHE) is associated with increased mortality. HE is commonly precipitated by infection, but whether HE predisposes to new infection is unclear. This study aimed to test if OHE predisposes to de novo infection during hospitalisation and its association with short-term mortality.

AIMS AND METHODS

Seven hundred and fifty-nine consecutive patients were identified at two institutions from prospectively maintained clinical databases of cirrhotic patients admitted with acute decompensation (AD). Infection and HE data were collected on the day of admission, and the occurrence of de novo infections was assessed for 28 days after admission. EASL-CLIF organ failure criteria were used to determine the presence of organ failures. Multivariable analysis using the logistic regression model was used to assess predictors of 28-day mortality and de novo infection.

RESULTS

Patients were divided into four groups; no baseline OHE or infection (n = 352); OHE with no baseline Infection (n = 221); no OHE but baseline infection (n = 100) and OHE with baseline infection (n = 86). On multivariate analyses, OHE (OR, 1.532 [95% CI, 1.061-2.300, P = 0.024]), and admission to ITU (OR, 2.303 [95% CI, 1.508-3.517, P < 0.001]) were independent risk factors for de novo infection. 28-day mortality was 25.3%, 60.2%, 55.0% and 72.1% in the 4-groups respectively. Age, INR and creatinine were independently predictive of mortality. The presence of overt HE, infection, coagulation, kidney, circulatory, respiratory and liver failures were significantly associated with higher mortality.

CONCLUSION

OHE is an independent risk factor for de novo infection in cirrhotic patients with AD.

摘要

背景

显性肝性脑病(OHE)的发生与死亡率增加有关。HE 通常由感染引发,但 HE 是否易引发新的感染尚不清楚。本研究旨在检验 OHE 是否易在住院期间引发新的感染及其与短期死亡率的关系。

目的和方法

从两家机构前瞻性维护的肝硬化患者急性失代偿(AD)入院临床数据库中确定了 759 例连续患者。入院当天收集感染和 HE 数据,并在入院后 28 天评估新感染的发生情况。采用 EASL-CLIF 器官衰竭标准确定器官衰竭的存在。采用逻辑回归模型的多变量分析用于评估 28 天死亡率和新发感染的预测因素。

结果

患者分为四组:无基线 OHE 或感染(n=352);无基线感染但有 OHE(n=221);无 OHE 但有基线感染(n=100)和有基线感染且有 OHE(n=86)。多变量分析显示,OHE(OR,1.532 [95%CI,1.061-2.300,P=0.024])和 ICU 入院(OR,2.303 [95%CI,1.508-3.517,P<0.001])是新发感染的独立危险因素。四组的 28 天死亡率分别为 25.3%、60.2%、55.0%和 72.1%。年龄、INR 和肌酐是死亡率的独立预测因素。显性 HE、感染、凝血、肾脏、循环、呼吸和肝脏衰竭的存在与更高的死亡率显著相关。

结论

OHE 是肝硬化 AD 患者新发感染的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4757/9303427/98c6a47d762e/APT-55-722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4757/9303427/98c6a47d762e/APT-55-722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4757/9303427/98c6a47d762e/APT-55-722-g002.jpg

相似文献

1
Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation.显性肝性脑病是肝硬化急性失代偿患者新发感染的独立危险因素。
Aliment Pharmacol Ther. 2022 Mar;55(6):722-732. doi: 10.1111/apt.16790. Epub 2022 Feb 1.
2
Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.经颈静脉肝内门体分流术后肝硬化患者显性肝性脑病新指标:营养状态评分。
Clin Nutr. 2022 Feb;41(2):560-566. doi: 10.1016/j.clnu.2021.12.036. Epub 2022 Jan 4.
3
Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.显性肝性脑病缓解后认知障碍的持续存在。
Gastroenterology. 2010 Jun;138(7):2332-40. doi: 10.1053/j.gastro.2010.02.015. Epub 2010 Feb 20.
4
Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.开发和验证 AMMON-OHE 模型,以预测肝硬化门诊患者显性肝性脑病发生的风险。
J Hepatol. 2023 Oct;79(4):967-976. doi: 10.1016/j.jhep.2023.05.022. Epub 2023 Jun 3.
5
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.自发性门体分流的总面积独立预测肝硬化肝性脑病和死亡率。
J Hepatol. 2020 Jun;72(6):1140-1150. doi: 10.1016/j.jhep.2019.12.021. Epub 2020 Jan 15.
6
Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis.临界闪烁频率测试可预测肝硬化患者显性肝性脑病和生存情况。
Dig Liver Dis. 2018 May;50(5):496-500. doi: 10.1016/j.dld.2018.01.133. Epub 2018 Jan 31.
7
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.经颈静脉肝内门体分流术后发作性显性肝性脑病不会增加肝硬化患者的死亡率。
J Hepatol. 2024 Apr;80(4):596-602. doi: 10.1016/j.jhep.2023.11.033. Epub 2023 Dec 13.
8
Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF).肝硬化患者因肝性脑病住院的特征、风险因素和死亡率,伴有和不伴有慢加急性肝衰竭(ACLF)。
J Hepatol. 2014 Feb;60(2):275-81. doi: 10.1016/j.jhep.2013.10.004. Epub 2013 Oct 12.
9
Disrupted topological organization of brain structural network associated with prior overt hepatic encephalopathy in cirrhotic patients.与肝硬化患者先前显性肝性脑病相关的脑结构网络拓扑组织紊乱。
Eur Radiol. 2018 Jan;28(1):85-95. doi: 10.1007/s00330-017-4887-8. Epub 2017 Jun 30.
10
Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study.维生素 D 缺乏使肝硬化患者发生隐性和显性肝性脑病的风险分层:一项回顾性队列研究。
Clin Nutr ESPEN. 2024 Oct;63:267-273. doi: 10.1016/j.clnesp.2024.06.055. Epub 2024 Jul 2.

引用本文的文献

1
Infection, inflammation and hepatic encephalopathy from a clinical perspective.从临床角度看感染、炎症与肝性脑病。
Metab Brain Dis. 2024 Dec;39(8):1689-1703. doi: 10.1007/s11011-024-01402-y. Epub 2024 Aug 30.
2
The Value of Ammonia as a Biomarker in Patients with Cirrhosis.氨作为肝硬化患者生物标志物的价值。
Semin Liver Dis. 2024 Aug;44(3):356-368. doi: 10.1055/a-2378-8942. Epub 2024 Aug 2.
3
Recurrence of portosystemic encephalopathy in cirrhotic patients and its risk factors.肝硬化患者门体分流性脑病的复发及其危险因素。

本文引用的文献

1
Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.抗生素预防时代急性静脉曲张出血患者的细菌感染
J Hepatol. 2021 Aug;75(2):342-350. doi: 10.1016/j.jhep.2021.03.026. Epub 2021 Jun 12.
2
Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF.代偿期肝硬化及 ACLF 患者血液免疫细胞特征。
Front Immunol. 2021 Feb 5;11:619039. doi: 10.3389/fimmu.2020.619039. eCollection 2020.
3
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):140-144. doi: 10.12669/pjms.40.1.8025.
4
Clinical Data based XGBoost Algorithm for infection risk prediction of patients with decompensated cirrhosis: a 10-year (2012-2021) Multicenter Retrospective Case-control study.基于临床数据的 XGBoost 算法预测失代偿期肝硬化患者感染风险:一项 10 年(2012-2021 年)多中心回顾性病例对照研究。
BMC Gastroenterol. 2023 Sep 13;23(1):310. doi: 10.1186/s12876-023-02949-3.
5
Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution.肝性脑病中的新旧诱因:对一个不断发展领域的新审视
J Clin Med. 2023 Feb 2;12(3):1187. doi: 10.3390/jcm12031187.
肝性脑病:分类、病理生理学和治疗的新见解。
J Hepatol. 2020 Dec;73(6):1526-1547. doi: 10.1016/j.jhep.2020.07.013. Epub 2020 Oct 21.
4
THE EFFECT OF OXIDATIVE STRESS ON THE AUTONOMIC NERVOUS SYSTEM IN PATIENTS WITH LIVER CIRRHOSIS.氧化应激对肝硬化患者自主神经系统的影响
Georgian Med News. 2020 Jan(298):94-99.
5
Acute-on-Chronic Liver Failure: A New Disease or an Old One Hiding in Plain Sight?慢加急性肝衰竭:一种新疾病还是一种早已存在却被忽视的疾病?
Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S45-S51. doi: 10.1002/cld.859. eCollection 2020 Feb.
6
Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis.对因肝硬化急性失代偿而住院的患者进行肝性脑病的连续评估。
Ann Hepatol. 2019 Mar-Apr;18(2):331-337. doi: 10.1016/j.aohep.2018.11.002. Epub 2019 Apr 15.
7
Prognostic Role of Ammonia in Patients With Cirrhosis.肝硬化患者氨的预后作用。
Hepatology. 2019 Sep;70(3):982-994. doi: 10.1002/hep.30534. Epub 2019 Mar 21.
8
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.全球肝硬化患者细菌感染的流行病学和影响。
Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
9
Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.欧洲失代偿期肝硬化和慢加急性肝衰竭患者中的多重耐药菌感染。
J Hepatol. 2019 Mar;70(3):398-411. doi: 10.1016/j.jhep.2018.10.027. Epub 2018 Nov 2.
10
Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure.验证 CLIF-C ACLF 评分是否能够确定慢性加急性肝衰竭患者接受强化治疗支持的无效阈值。
Crit Care. 2018 Oct 10;22(1):254. doi: 10.1186/s13054-018-2156-0.